𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes

✍ Scribed by Eugene L. Asahchop; Maureen Oliveira; Bluma G. Brenner; Jorge L. Martinez-Cajas; Thomas d’Aquin Toni; Michel Ntemgwa; Daniela Moisi; Serge Dandache; Brent Stranix; Cecile L. Tremblay; Mark A. Wainberg

Book ID
113458408
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
185 KB
Volume
87
Category
Article
ISSN
0166-3542

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PL-100, a novel HIV-1 protease inhibitor
PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: An in vitro selection study
✍ Serge Dandache; Craig A. Coburn; Maureen Oliveira; Timothy J. Allison; M. Kathar 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB

## Abstract The development of new HIV inhibitors with distinct resistance profiles is essential in order to combat the development of multi‐resistant viral strains. A drug discovery program based on the identification of compounds that are active against drug‐resistant viruses has produced PL‐100,

Co-circulation HIV-1 subtypes B, C, and
Co-circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-naïve population from Southernmost Brazil: Analysis of primary resistance mutations
✍ Rúbia Marília de Medeiros; Dennis Maletich Junqueira; Maria Cristina Cotta Matte 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

## Abstract In Southernmost Brazil HIV‐1 subtypes B, C, and CRF31\_BC co‐circulates and, since 1996 with the implementation of free access to highly active antiretroviral treatment (HAART), this epidemic is under a quite characteristic selective pressure. The profile of mutations and polymorphisms